NCT02239731View on ClinicalTrials.gov

Safety, Tolerability and Efficacy Study of Doxycycline Foam for the Prevention of EGFRI Skin Toxicity in Cancer Patients

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 31, 2014

Primary Completion Date

October 31, 2015

Study Completion Date

October 31, 2015

Conditions

Rash Due to Epidermal Growth Factor Receptor Inhibitors

Interventions

DRUG

FDX104 (4% Doxycycline)

FDX104 - 4% or Placebo to be applied twice twice daily during 5 weeks

Trial Locations (7)

64239

Sourasky medical center, Tel Aviv

Unknown

Soroka Medical Center, Beersheba

Rambam Medical Center, Haifa

Hadassah Medical Center, Jerusalem

Rabin Medical Center, Petah Tikva

Assaf Harofeh medical center, Rishon LeZiyyon

Sheba medical center, Tel Litwinsky

All Listed Sponsors

lead

Vyne Therapeutics Inc.

INDUSTRY

NCT02239731 - Safety, Tolerability and Efficacy Study of Doxycycline Foam for the Prevention of EGFRI Skin Toxicity in Cancer Patients | Biotech Hunter | Biotech Hunter